N-Terminal Prodomain of Pfs230 Synthesized Using a Cell-Free System Is Sufficient To Induce Complement-Dependent Malaria Transmission-Blocking Activity†

Mayumi Tachibana,1 Yimin Wu,2 Hideyuki Iriko,3 Olga Muratova,2 Nicholas J. MacDonald,2 Jetsumon Sattabongkot,4† Satoru Takeo,5 Hitoshi Otsuki,3 Motomi Torii,1,6†* and Takaumi Tsuboi1,5,6,7†

Department of Molecular Parasitology, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Rockville, Maryland 20852; Division of Medical Zoology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand; Cell-Free Science and Technology Research Center and Venture Business Laboratory, Ehime University, Matsuyama, Ehime 790-8577, Japan; and Ehime Proteo-Medicine Research Center, Ehime University, Toon, Ehime 791-0295, Japan

Received 20 April 2011/Returned for modification 2 June 2011/Accepted 19 June 2011

Malaria is a major infectious disease caused by protozoa of the genus Plasmodium and is transmitted by anopheline mosquitoes. There were an estimated 225 million clinical cases of malaria and 781,000 malaria-related deaths in 2009 (39). Among four species of human malaria parasites, Plasmodium falciparum causes the most severe form of malaria and is globally distributed. Elimination strategies are, however, limited and confounded by the emergence of multidrug-resistant parasites. In this study, we used the wheat germ cell-free expression system to produce N-terminal fragments of Pfs230 and evaluated the transmission-blocking activity of antisera against the recombinant Pfs230 protein. The rabbit antisera reacted to the surface of cultured gametocytes and gametes of the Plasmodium falciparum NF54 line, recognized the 360-kDa form of parasite-produced Pfs230 by Western blot assay, and reduced the infectivity of NF54 parasites to Anopheles stefensi mosquitoes in the presence of complement in a standard membrane feeding assay. Thus, our data demonstrate that the N-terminal pro domain of Pfs230 is sufficient to induce complement-dependent transmission-blocking activity against P. falciparum.
1A) (6, 11, 36) and elicits a humoral immune response in infected individuals that can mediate transmission-blocking immunity (12, 16). Consequently, Pfs230 as a component of a vaccine offers the advantage that it will elicit an immune response that is boosted by natural infection and will thus provide long-lasting immunity (3, 28).

The monoclonal antibodies (MAbs) recognizing the CM domain of Pfs230 potently block the infectivity of the *P. falciparum* parasites to mosquitoes (26, 28, 29, 37). Several regions of Pfs230 have been expressed as maltose-binding protein (MBP) fusions in *Escherichia coli* (designated r230/MBP) (43). Antibodies raised against an N-terminal 76-kDa fragment of Pfs230 designated r230/MBP.C (amino acids 443 to 1132) were bound to the surfaces of gametes and reduced the infectivity of *P. falciparum* to mosquitoes in the presence of complement (43). This was the first demonstration of the transmission-blocking activity of antibodies against a recombinant Pfs230 antigen. However, r230/MBP.C protein elicited incomplete oocyst reduction. Attempts to increase the efficacy of Pfs230C-based vaccines have included yeast expression systems (38), DNA vaccine (9), and vaccinia virus expression systems (40). Disappointingly, these attempts to produce a more efficacious vaccine have failed, with r230/MBP.C appearing to be the most potent Pfs230 TBV identified to date (40). Recently, we reported that among the various protein synthesis systems, the wheat germ cell-free protein synthesis system is permissive for the production of correctly folded malaria proteins (30, 32). The wheat germ cell-free system was demonstrated to produce the Pfs230C and its truncated forms and to characterize the minimal region that contains the immunodominant epitope(s) of Pfs230C sufficient to induce malaria transmission-blocking activity.

### MATERIALS AND METHODS

Cloning of fragments encoding truncated forms of Pfs230. Williamson et al. (43) predicted the CM domains, CM1 through CM7, in Pfs230 (PFB0405w) (Fig. 1A). Gerloff et al. (11) also described cysteine-rich domains I through XIV in Pfs230. Based on those predictions, we synthesized four different truncated forms of Pfs230, i.e., Pfs230C (pro domain through domain III, amino acids 443 to 1132 with 13 cysteines), Pfs230C2 (pro domain through domain II, amino acids 443 to 915 with 8 cysteines), Pfs230C1 (pro domain and domain I, amino acids 443 to 715 with 8 cysteines), and Pfs230C0 (pro domain, amino acids 443 to 588 without any cysteines) (Fig. 1B). Genomic DNA encoding each of the truncated forms of Pfs230C was amplified by PCR from *P. falciparum* 3D7 DNA and cloned between the XhoI and NotI sites of plasmid pMEU-E01-GST-TEV (a vector with an N-terminal glutathione S-transferase tag followed by a tobacco etch virus protease cleavage site; CellFree Sciences, Matsuyama, Japan). The internal nucleotide sequences were confirmed using the ABI PRISM 3130 Genetic Analyser and the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA).

### Production and purification of truncated Pfs230 proteins.

Recombinant proteins Pfs230C, Pfs230C2, Pfs230C1, and Pfs230C0 were produced with the wheat germ cell-free protein expression system by the bilayer translation reaction method described previously (33, 34). After their synthesis, the truncated forms of Pfs230C were affinity purified by passage through a glutathione-Sepharose 4B column (GE Healthcare, Camarillo, CA) and eluted by on-column cleavage with AcTEV protease (Invitrogen, Carlsbad, CA) after extensive washing of the column with phosphate-buffered saline (PBS). Concentrations of purified proteins were determined using the Bradford protein assay kit (Bio-Rad Laboratories, Hercules, CA). Protein samples were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, and the bands were visualized with Coomassie brilliant blue (Fig. 2). Purified protein samples were stored in aliquots at −80°C until further use.

### Preparation of rabbit antisera.

A Japanese White rabbit for each antigen was immunized subcutaneously 3 times at 3-week intervals with 250 μg of each purified truncated Pfs230 protein emulsified with complete Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO) for the prime and with incomplete Freund’s adjuvant (Sigma-Aldrich) for the first and the second boosts. Blood was collected before immunization and 2 weeks after the third immunization. Antisera were prepared as previously described (25). Preimmune sera from individual rabbits were used as controls. All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of Ehime University, and the experiments were conducted according to the Ethical Guidelines for Animal Experiments of Ehime University.

### Enzyme-linked immunosorbent assay (ELISA).

The titers of the IgG in the rabbit antisera raised against different truncated Pfs230 proteins were measured by ELISA. Briefly, 96-well MaxiSorp ELISA plates (Nunc, Rochester, NY) were coated with 0.5 μg/ml recombinant truncated forms of Pfs230 in 20 mM borate buffer (pH 8.9) and incubated overnight at 4°C. After blocking with 2 mg/ml gelatin in 20 mM borate buffer, serum samples were plated in duplicate at a starting dilution of 1:100 with PBS containing 0.01% Tween 20 and 2 mg/ml gelatin and titrated in 10-fold dilutions. Target-specific IgG was detected using horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG at 1:2,000 (Bio-source, Camarillo, CA) and visualized using 2,2′-azinobis(3-ethylbenzthiazoline-sulfonic acid) (ABTS; Wako, Osaka, Japan) as the substrate. The reaction was then stopped with 0.1 M citric acid, and the optical density values were measured. Reciprocal serum dilutions that gave a mean absorbance value of 0.5 at 415 nm were determined as the endpoint titers. In order to measure the antibody titers against native Pfs230 protein, stage V gametocyte of the *P. falciparum* NF54 line was extracted with PBS with 1% Triton X-100 containing Complete Proteinase Inhibitor Cocktail (Roche, Indianapolis, IN) and centrifuged at 21,900 g for 20 min. The collected supernatant was diluted to a final concentration of 1.0 μg/ml and used as a capture antigen, and ELISA was performed as described above.

### Immunofluorescence assay (IFA).

An indirect IFA was performed with cultured gametocytes or macrogametes/zygotes after the induction of gametogenesis from the cultured gametocytes of the *P. falciparum* NF54 line (43). Air-dried thin smears of the parasites were prepared on glass slides and stored at −80°C.
untill use. The smears were thawed, fixed with ice-cold acetone for 3 min, and blocked with PBS containing 5% nonfat milk (PBS milk) at 37°C for 30 min. They were then incubated with either rabbit immune serum (1:500 dilution) or matched preimmune serum as a negative control at 37°C for 1 h, followed by incubation with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen) as a secondary antibody (1:500) at 37°C for 30 min. The smears were then incubated with either rabbit immune serum (1:500 dilution) or matched preimmune serum as a negative control at 37°C for 1 h, followed by incubation with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen) as a secondary antibody (1:500) at 37°C for 30 min. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; 2 μg/ml) mixed with a secondary antibody solution. Slides were mounted in ProLong Gold Antifade reagent (Invitrogen) and observed under a 63× oil immersion lens. High-resolution image capture and processing were performed using a confocal scanning laser microscope (LSM5 PASCAL; Carl Zeiss MicroImaging, Thornwood, NY). Images were processed in Adobe Photoshop (Adobe Systems Inc., San Jose, CA).

**Western blot analysis.** Proteins of the cultured gametocytes were extracted in nonreducing SDS-PAGE loading buffer and boiled at 98°C for 3 min, and extract from approximately 10^5 gametocytes per lane was subjected to electrophoresis on a 12.5% polyacrylamide gel (ATTO, Tokyo, Japan). Proteins were then transferred to a 0.2-μm polyvinylidene fluoride (PVDF) membrane (GE Healthcare). The proteins were immunostained with either preimmune or immune serum as the primary antibody. To ensure that equal amounts of the protein samples were loaded in each lane for Western blot analysis, the membranes were simultaneously probed with anti-PFHSF70 mouse MAb (4C9) as a quantitative marker for parasitic proteins (35). To ensure that equal amounts of the protein samples were loaded in each lane for Western blot analysis, the membranes were simultaneously probed with anti-PFHSF70 mouse MAb (4C9) as a quantitative marker for parasitic proteins (35). The membranes were then probed by HRP-conjugated goat anti-rabbit IgG antibody (GE Healthcare) together with HRP-conjugated goat anti-mouse IgG antibody (GE Healthcare) and visualized with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA) on a LAS 4000 mini luminescent image analyzer (GE Healthcare). The relative molecular masses of the proteins were estimated with reference to Precision Plus Protein Standards (Bio-Rad, Hercules, CA).

**Transmission-blocking assays.** The transmission-blocking activity of the sera was tested by an ex vivo standard membrane feeding assay (SMFA) as described previously (44). Briefly, an in vitro gametocyte culture of *P. falciparum* (NF54 line) was evaluated for the percentage of stage V gametocytes (>0.5%), and the vitality of exflagellation centers was observed at ×400 magnification. The gametocyte pellet was diluted with normal O^- red blood cells (Interstate Blood Bank, Memphis, TN) and a normal heat-inactivated (complement minus) serum pool (Interstate Blood Bank, Memphis, TN) to achieve a 0.15% ± 0.05% concentration of stage V gametocytes and a hematocrit of 50%. This infected blood mixture was kept at 37°C and aliquoted into 200-μl portions prior to feeding. One 200-μl aliquot of “infected blood” was mixed with 60 μl of the test serum diluted with a normal heat-inactivated O^- human serum pool at 1:1, 1:2, or 1:4 for final dilution of the sera in feeders at 1:5, 1:11, and 1:21, respectively. The mixture was immediately fed to 3- to 8-day-old *Anopheles stephensi* (Nijmegen strain) mosquitoes prestared for 24 to 30 h through a membrane feeding apparatus using a thin stretched Parafilm membrane. Mosquitoes were kept for 7 to 8 days after feeding at 26°C under high-humidity conditions to allow parasites to develop into oocytes. Infectivity was measured by dissecting at least 20 mosquitoes per sample, staining the midguts with a 0.05% merbromin (Mercurochrome) solution in water for at least 20 min, and counting the oocysts in each midgut. The percent reduction of the oocyst count per mosquito was determined by the formula 100 × (mean oocyst no. of negative control − mean oocyst no. of antigen)/mean oocyst no. of negative control, where the negative-control feeding used preimmune serum from the same rabbit. All samples or diluted samples were tested in replicate. To verify whether the difference in oocyst numbers between preimmune and immune groups is statistically significant, data were analyzed by comparing the medians of two groups using the Mann-Whitney U test. Oocyst prevalence was statistically analyzed for all vaccination regimens by Fisher's exact test. Probability (P) values of less than 0.05 were considered statistically significant in both analyses.

**RESULTS**

**Synthesis of soluble Pfs230C proteins in a wheat germ cell-free system.** In order to evaluate the transmission-blocking activities elicited by the wheat germ cell-free expressed truncated forms of Pfs230C and to define the minimal region of Pfs230 sufficient to induce the malaria transmission-blocking activity, we designed different Pfs230C constructs, i.e., Pfs230C (pro domain through domain III, amino acids 443 to 1132 with 13 cysteines), Pfs230C2 (pro domain through domain II, amino acids 443 to 915 with 8 cysteines), Pfs230C1 (pro domain and domain I, amino acids 443 to 715 with 4 cysteines), and Pfs230C0 (pro domain, amino acids 443 to 588 without any cysteines), based on schematic diagrams of Pfs230 (Fig. 1A and B) without codon optimization and expressed them in a wheat germ cell-free system (Fig. 2). Figure 2 shows the different truncated Pfs230 proteins resolved in a 12.5% SDS-polyacrylamide gel. Almost all of the truncated Pfs230 proteins were recovered in the supernatant fraction and easily purified as a single dominant band (Fig. 2, arrows) along with other, non-specific, faint bands by affinity chromatography in lanes C2 and C. The yields of purified Pfs230C0, Pfs230C1, Pfs230C2, and Pfs230C proteins were 62, 54, 65, and 75 μg/5.0 ml of the reaction mixture, respectively. These results demonstrate that the wheat germ cell-free system is able to translate the native Pfs230 gene sequences and produce soluble proteins.

**Rabbit antibodies against truncated forms of Pfs230C recognized native parasite proteins.** To evaluate the immunogenicity of the recombinant truncated forms of Pfs230, rabbit antisera were collected on study days 0 (pre) and 56 (post). ELISA analysis of the IgG responses elicited by the four truncated forms of Pfs230C (Fig. 3A) showed that all of the postimmune sera contained high titers of antibodies, with no discernible difference among the four recombinant protein formulations, i.e., titers against all of the recombinant proteins, Pfs230C0 (10^5.3), Pfs230C1 (10^5.1), Pfs230C2 (10^5.8), and Pfs230C (10^5.6) (Fig. 3A).
All of the negative-control preimmune sera showed no IgG responses (Fig. 3A).

To evaluate the immunoreactivity of the antisera against parasite-derived native proteins, Western blot analysis was performed. Extract from stage V gametocytes of the \textit{P. falciparum} NF54 line was separated by 12.5% SDS-PAGE, and specific bands with the expected mobility of native Pfs230 protein (Fig. 4, arrow) were detected under nonreducing conditions (Fig. 4, left panel) using antiserum against each recombinant Pfs230 protein. Preimmune serum failed to recognize the native Pfs230 protein (Fig. 4, right panel). These results suggest that the recombinant truncated forms of Pfs230C prepared by the cell-free system as soluble proteins retained native epitopes.

To ensure that the same amount of each gametocyte protein sample was loaded in each lane for Western blot analysis, the membranes were also probed with anti-PfHSP70 MAb (4C9) (35). The intensities of the PfHSP70 bands indicated that the amounts of samples loaded in the lanes were comparable (Fig. 4, arrowhead). Importantly, ELISA analysis of the IgG responses elicited by the four truncated forms of Pfs230C showed that the postimmune serum against each recombinant protein, Pfs230C0 (titer, $10^{3.5}$), Pfs230C1 (titer, $10^{3.3}$), Pfs230C2 (titer, $10^{3.7}$), or Pfs230C2 (titer, $10^{2.4}$) contained significant levels of antibodies with no discernible difference in the levels of antibodies against the parasites’ native Pfs230 protein extracted from the gametocytes of \textit{P. falciparum} (Fig. 3B).

To confirm the specificity of the antisera for the truncated forms of Pfs230, IFA was performed against stage V gametocytes and gametes of \textit{P. falciparum} (Fig. 5). Antisera against the recombinant truncated forms of Pfs230 specifically stained the surfaces of both gametocytes and gametes (Fig. 5). All of the negative-control preimmune sera showed no staining of the parasites (data not shown).

Antibodies against truncated forms of Pfs230 reduce parasite transmission to the mosquito vector in the presence of complement. The transmission-blocking activity of the rabbit antisera raised against recombinant Pfs230C was evaluated by SMFA. The antisera were diluted to minimize nonspecific effects of sera on transmission-blocking activity, and the preimmune sera from individual animals were used as negative controls. The multiple assays were performed on different days using the cultured \textit{P. falciparum} NF54 line (Table 1). The number of oocysts formed in the presence of complement in experiment 1 was significantly lower ($P < 0.0001$), by 86%, than that obtained with the preimmune serum (with complement, experiment 1). A similar result (88% reduction) was obtained ($P < 0.0001$) in experiment 2 (with complement,
experiment 2). In the third experiment (Table 1), a further reduction was observed ($P < 0.0001$, 99.0%) when a 1:5.3 dilution of anti-Pfs230C antiserum was tested in the presence of complement. The number of oocysts was inversely proportional to the concentration of antiserum added (experiment 3 in Table 1), and the differences between pre- and postimmune groups, even at the lowest concentration of the antiserum (1:21) tested were still significant ($P < 0.0001$).

To identify the minimal functional transmission-blocking domains within Pfs230C, the complement-dependent transmission-blocking activity was also evaluated in sera raised against Pfs230C0, -C1, and -C2 (Fig. 1B). As shown in Table 1, the antisera raised against Pfs230C0, -C1, and -C2 (with complement, experiment 4) significantly reduced the number of oocysts per mosquito if complement was present in the SMFA. Surprisingly, the rabbit antiserum (other than anti-Pfs230C0) reduced oocyst formation significantly in the mosquito, even in the absence of complement (without complement, experiment 4). Consistent with observations in SMFAs in general, the apparent transmission-blocking efficacy was lower when the oocyst load of the preimmune control was higher (Table 1, experiment 5).

The oocyst prevalence, expressed as the number of oocyst-positive mosquitoes over the total number of mosquitoes dissected (numbers infected/dissected in Table 1), was statistically analyzed for all vaccination regimens by Fisher's exact test. Both the number of oocyst and the oocyst prevalence in mosquitoes were significantly reduced by the Pfs230C (1:5.3) antiserum in experiment 3 and the Pfs230C0 (1:5.3), Pfs230C1 (1:5.3), and Pfs230C2 (1:5.3) antiseras in experiment 5.

**DISCUSSION**

We have demonstrated that the wheat germ cell-free system supported the production of soluble recombinant Pfs230C (comprising amino acids 443 to 1132 of Pfs230), which induced transmission-blocking antibodies (Table 1). In previous studies (4, 43), transmission-blocking antibodies against Pfs230C were effective only at a higher concentration (i.e., a 1:2 dilution).

However, in this study, the transmission-blocking antibodies induced by Pfs230C were effective even at a lower concentration (i.e., a 1:5.3 dilution). The specific IgG titers of these immune sera were comparable when they were tested against the immunizing antigens; the IgG titers of the anti-Pfs230C2 serum was slightly lower than those of the other sera when they were tested against native, parasite-derived Pfs230. The transmission-blocking efficacy is complement dependent, as previously reported (40). Moreover, even when the antiserum was further diluted (1:21 dilution in Table 1, experiment 3), a 70% reduction of the oocyst number was still achieved ($P < 0.0001$). These results suggest that the transmission-blocking efficacy seen is comparable to that of *E. coli*-produced recombinant Pfs230C, i.e., r230/MBP.C comprising amino acids 443 to 1132.

Evidence from previous studies and the data presented herein that recombinant Pfs230C has transmission-blocking activity, defining a minimal region of Pfs230 sufficient to induce the malaria transmission-blocking activity, will facilitate the development of candidate Pfs230 TBV into a vaccine. Bustamante et al. (4) expressed the regions of recombinant truncated Pfs230 proteins in *E. coli* as MBP fusions, i.e., r230/MBP.C (amino acids 443 to 1132), r230/MBP.C5’ (amino acids 443 to 791), r230/MBP.CM1 (amino acids 583 to 913), r230/MBP.C1.6 (amino acids 453 to 913), and r230/MBP.C2 (amino acids 914 to 1268), and used them to generate antibodies in mice. All of the antiseras recognized native Pfs230 on the surfaces of the gametes, but only antibodies against r230/MBP.C, and not antibodies against other truncated forms, reduced the number of oocysts. The authors therefore concluded that the entire Pfs230C protein is required to produce the transmission-blocking epitope (4). However, our results demonstrate that antibodies against all of the recombinant truncated forms of Pfs230 reduced the number of oocysts not only in the presence but even in the absence of active complement (Table 1). The reason for the transmission-blocking activity in the absence of active complement may be due to the presence of antibodies that block biological function such as blocking of the fertilization of gametes besides the antibodies that are involved in the complement-mediated lysis of gametes in polyclonal antibodies. These results demonstrate that the topology of the native Pfs230 domains may be better retained in the recombinant truncated forms of Pfs230 synthesized in the eukaryotic wheat germ cell-free system than in the proteins expressed in *E. coli*. Importantly, there is no obvious difference in the transmission-blocking efficacy of antibodies raised against Pfs230C0, -C1, or -C2. This suggests that the transmission-blocking epitope is confined to the N-terminal cysteine-free pro domain (Pfs230C0). Therefore, the entire Pfs230C protein is not required for immunization to induce complement-dependent transmission-blocking activity against *P. falciparum*, but the minimal N-terminal cysteine-free pro domain (Pfs230C0) is sufficient (Table 1, experiments 4 and 5).

Several TBV candidates have complex structures and multiple disulfide bonds, which hamper their production, evaluation, and development as recombinant vaccine candidates (18, 19). However, the N-terminal pro domain of Pfs230 (Pfs230C0) is cysteine free and hence not constrained by disulfide bonds. The absence of disulfide bonds is expected to facilitate the production and development of Pfs230C0 as a TBV candidate. Future vaccine development efforts should...
It is critical to design a vaccine based on sequences with minimum polymorphisms to avoid parasite evasion of vaccine-induced immunity. The native Pfs230 protein is expressed on the surface of gametocytes, and field studies have found that antibodies against Pfs230 are generated during natural infection (12, 16). Exposure to host immune pressure has resulted in Pfs230 sequence polymorphisms observed in field isolates (11, 24, 42). A compilation of single nucleotide polymorphisms (SNPs) in Pfs230 sequences from 13 laboratory strains deposited in PlasmoDB (http://plasmodb.org/plasmo/) showed that Pfs230C contains a total of 10 nonsynonymous SNPs. Pfs230C2 and Pfs230C1 contain 4 of them, and, importantly, Pfs230C0 does not contain any nonsynonymous SNPs (Table 2). These data further support the notion that Pfs230C0 is a promising TBV candidate.

Production of functionally active truncated forms of Pfs230 will also facilitate understanding of the dynamics of naturally acquired transmission-blocking immunity and assist with the future evaluation and deployment of TBVs in populations living in areas where malaria is endemic. Recently Bousema et al.

| Table 1: Evaluation of sera from rabbits immunized with Pfs230Cs by SMFA* |
|-----------------------------|------------------------|------------------------|------------------------|
| Antigen and exp no. (dilution) | Sample | With complement | Without complement |
|                             |           | No. inf./diss. | Median (IQR) | % Reduction | P           | No. inf./diss. | Median (IQR) | % Reduction | P           |
| Pfs230C | 1 (1:5.3) | Rabbit 2 | 24/25 | 14.0 (8.5–33.0) | 86 | <0.0001 | 22/24 | 12.5 (5.0–41.5) | 34 | NS |
|         | 1 (1:5.3) | Rabbit 2 | 18/23 | 2.0 (1.0–4.0) |   |          | 23/25 | 11.0 (5.5–26.0) |   |          |
| Pfs230C | 2 (1:5.3) | Rabbit 2 | 23/23 | 21.0 (11.0–28.0) | 88 | <0.0001 | 23/24 | 17.0 (8.0–20.0) |   |          |
|         | 2 (1:5.3) | Rabbit 2 | 21/23 | 2.0 (1.0–3.5) |   |          | 23/25 | 8.0 (5.5–15.5) |   |          |
| Pfs230C | 3 (1:5.3) | Rabbit 2 | 21/22 | 57.0 (30.0–76.0) | 99 | <0.0001 | 23/24 | 11.0 (5.5–26.0) |   |          |
|         | 3 (1:5.3) | Rabbit 2 | 20/21 | 3.0 (1.0–6.5) |   |          | 23/25 | 8.0 (5.5–15.5) |   |          |
| Pfs230C | 3 (1:11) | Rabbit 2 | 22/22 | 55.0 (37.0–73.0) | 94 | <0.0001 | 23/25 | 8.0 (5.5–15.5) |   |          |
|         | 3 (1:21) | Rabbit 2 | 23/24 | 16.5 (12.0–24.0) | 70 | <0.0001 | 23/25 | 8.0 (5.5–15.5) |   |          |
| Pfs230C0 | 4 (1:5.3) | Rabbit 100 | 21/21 | 111.0 (78.5–134.5) | 82 | <0.0001 | 22/22 | 58.0 (39.5–105.0) |   |          |
|         | 4 (1:5.3) | Rabbit 100 | 20/23 | 20.0 (13.0–28.0) |   |          | 20/21 | 53.0 (33.0–82.5) |   |          |
| Pfs230C1 | 4 (1:5.3) | Rabbit 101 | 21/21 | 81.0 (66.0–120.0) | 63 | <0.0001 | 24/24 | 53.5 (16.5–83.5) | 38 | <0.01 |
|         | 4 (1:5.3) | Rabbit 101 | 22/22 | 30.5 (14.5–45.5) |   |          | 24/24 | 53.5 (16.5–83.5) |   |          |
| Pfs230C2 | 4 (1:5.3) | Rabbit 102 | 21/21 | 120.0 (80.0–166.5) | 71 | <0.0001 | 21/21 | 67.0 (39.5–90.0) |   |          |
|         | 4 (1:5.3) | Rabbit 102 | 22/22 | 33.5 (20.5–52.5) |   |          | 26/26 | 38.0 (16.0–63.5) | 46 | <0.05 |
| Pfs230C0 | 5 (1:5.3) | Rabbit 100 | 18/22 | 2.0 (1.0–5.0) | 92 | <0.0001 | 23/23 | 15.0 (10.0–21.0) | 62 | <0.0001 |
|         | 5 (1:5.3) | Rabbit 100 | 6/28* | 0.0 (0.0–0.0) |   |          | 24/24 | 5.0 (3.0–7.5) |   |          |
| Pfs230C1 | 5 (1:5.3) | Rabbit 101 | 22/22 | 6.0 (3.0–8.0) | 92 | <0.0001 | 22/24 | 14.0 (8.5–16.0) | 41 | <0.05 |
|         | 5 (1:5.3) | Rabbit 101 | 8/23* | 0.0 (0.0–1.0) |   |          | 22/24 | 6.5 (2.5–10.0) |   |          |
| Pfs230C2 | 5 (1:5.3) | Rabbit 102 | 18/24 | 2.5 (0.5–4.0) | 79 | <0.0001 | 28/28 | 9.0 (5.5–15.5) | 48 | <0.01 |
|         | 5 (1:5.3) | Rabbit 102 | 8/23* | 0.0 (0.0–1.0) |   |          | 25/25 | 6.0 (3.5–8.0) |   |          |

* One 200-μl aliquot of “infected blood” with a hematocrit of 50% was mixed with 60 μl of the test serum diluted with a normal heat-inactivated O human serum pool in a 1:1, 1:2, or 1:4 final dilution of the sera in feeders at 1:5.3, 1:11, and 1:21, respectively. The serum sample from an individual rabbit was used. Numbers such as 2, 100, 101, and 102 are animal identification numbers. Oocyst prevalence, expressed as the number of oocyst-infected mosquitoes over the total number of mosquitoes dissected (inf./diss.), was statistically analyzed between pre- and postimmune serum groups for all vaccination regimens by Fisher’s exact test. Statistically significant, P < 0.05. IQR, interquartile range. Percent reduction in the oocyst count per mosquito was determined by the formula 100 × (mean oocyst no. negative control − mean oocyst no. test)/mean oocyst no. negative control, where the negative-control feeding used preimmune serum from the same rabbit. The median number of oocysts was statistically analyzed by comparing the day 56 immune serum with the matched preimmune rabbit serum (Mann-Whitney U test), and P values were obtained. NS, not significant.
on the plant-based transient protein expression system applied for clinical studies. Therefore, expression trials based using the cell-free system for the production of recombinant clinical studies. However, to date, there is no cGMP facility for cell-free protein synthesis for the production of Pfs230C for limiting.

A large-scale seroepidemiological surveillance will no longer be cated forms of Pfs230 in large quantities using the wheat germ protein. It has proven that we could synthesize properly folded soluble truncated forms of Pfs230 using the wheat germ system. These truncated forms are expected to be useful for a variety of applications, including vaccine development.

Our study has shown that truncated forms of Pfs230 can be produced in the wheat germ system, which is a promising alternative to traditional insect cell systems. However, further optimization of the expression conditions and the development of a cGMP facility are required to produce Pfs230 in large quantities for clinical trials.

The present study demonstrates the potential of wheat germ cell-free protein synthesis for the production of Pfs230C for clinical studies. However, to date, there is no cGMP facility using the cell-free system for the production of recombinant proteins for clinical studies. Therefore, expression trials based on the plant-based transient protein expression system applicable to the downstream cGMP (23) are under way toward the development of Pfs230-based TBV (10).

ACKNOWLEDGMENTS

We thank Thangavelu U. Arumugam for critical reading of the manuscript. This research was supported in part by the Ministry of Education, Culture, Sports, Science and Technology (21022034, 21249028, 21406010) and by the Ministry of Health, Labor, and Welfare, Japan (H20-Shinkou-ippan-013, H21-Chikyukibo-ippan-005). This work was also supported in part by a grant from The Bill and Melinda Gates Foundation.

REFERENCES

1. Birckett, A. J. 2010. PATH malaria vaccine initiative (MVI): perspectives on the status of malaria vaccine development. Hum. Vaccin. 6:139–145.
2. Boussoua, J. T., et al. 2006. Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in Papua, Indonesia. Am. J. Trop. Med. Hyg. 74:425–431.
3. Boussoua, T., et al. 2010. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pf48/45 in a low endemic area in Tanzania. PLoS One 5:e14114.
4. Bustamante, P. J., et al. 2000. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol. 22:373–380.
5. Carter, R. 2001. Transmission blocking malaria vaccines. Vaccine 19:2369–2374.
6. Carter, R., A. Coulson, S. Bhatti, B. J. Taylor, and J. F. Elliott. 1995. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 181:135–147.
7. Duffy, P. E., and D. C. Kaslow. 1997. A novel malaria protein, Pf28, and Pf62 are genetically linked and synergistic as falciparum malaria transmission-blocking antigens. Infect. Immun. 65:1109–1113.
8. Fanning, S. L., et al. 2003. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen. Pfs230. Vaccine 21:3228–3235.
9. Farrance, C. E., et al. 2011. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin. Vaccine Immunol. 18:1351–1357.
10. Gravett, P. M., A. Creasey, S. Maslau, and R. Carter. 2005. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 102:13598–13603.
11. Graves, P. M., R. Carter, T. R. Burkot, I. A. Quakyi, and N. Kumar. 1988. Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera. Parasite Immunol. 10:209–218.
12. Greenwood, B. 2009. Can. malaria be eliminated? Trans. R. Soc. Trop. Med. Hyg. 103(Suppl. 1):S2–S5.
13. Greenwood, B., and G. Targett. 2009. Do we still need a malaria vaccine? Parasite Immunol. 31:582–586.
14. Greenwood, B. M., et al. 2008. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118:1266–1276.
15. Healer, J., D. McGuinness, R. Carter, and E. Riley. 1999. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 119:425–433.
16. Hisaeda, H., et al. 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs39 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:6616–6623.
17. Kaslow, D. C. 2002. Transmission-blocking vaccines. Chem. Immunol. 80:287–307.
18. Kaslow, D., C. M., et al. 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:5576–5580.
20. Kaslow, D. C., et al. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74–76.

21. Kocken, C. H., et al. 1993. Cloning and expression of the gene coding for the transmission blocking target antigen Pf64/45 of Plasmodium falciparum. Mol. Biochem. Parasitol. 61:59–68.

22. Malkin, E. M., et al. 2005. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23:3131–3138.

23. Musiychuk, K., et al. 2007. A launch vector for the production of vaccine antigens in plants. Influenza Other Respi. Viruses 1:19–25.

24. Niederwieser, I., I. Felger, and H. P. Beck. 2001. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am. J. Trop. Med. Hyg. 64:9–11.

25. Otsuki, H., et al. 2009. Single amino acid substitution in Plasmodium yoelii erythrocyte ligand determines its localization and controls parasite virulence. Proc. Natl. Acad. Sci. U. S. A. 106:7167–7172.

26. Quakyi, I. A., et al. 1987. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 139:2113–2117.

27. Quakyi, I. A., et al. 1989. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens. Am. J. Trop. Med. Hyg. 41:125–134.

28. Read, D., et al. 1994. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pf230 are all complement-fixing. Parasite Immunol. 16:511–519.

29. Rener, J., P. M. Graves, R. Carter, J. L. Williams, and T. R. Burkot. 1983. Target antigens of transmission-blocking immunity on gametocytes of Plasmodium falciparum. J. Exp. Med. 158:976–981.

30. Takeo, S., T. U. Arumugam, M. Torii, and T. Tsuboi. 2009. Wheat germ cell-free technology for accelerating the malaria vaccine research. Expert Opin. Drug Discov. 4:1191–1199.

31. Tsuboi, T., et al. 1998. Sequence polymorphism in two novel Plasmodium vivax ookinetе surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4:772–782.

32. Tsuboi, T., S. Takeo, T. U. Arumugam, H. Otsuki, and M. Torii. 2010. The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery. Acta Trop. 114:171–176.

33. Tsuboi, T., et al. 2008. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 76:1702–1708.

34. Tsuboi, T., S. Takeo, T. Sawasaki, M. Torii, and Y. Endo. 2010. An efficient approach to the production of vaccines against the malaria parasite. Methods Mol. Biol. 607:73–83.

35. Tsuji, M., D. Mattei, R. S. Nussenzweig, D. Eichinger, and F. Zavala. 1994. Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol. Res. 80:16–21.

36. van Dijk, M. R., et al. 2010. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog. 6:e1000853.

37. Vermeulen, A. N., et al. 1985. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 162:1460–1476.

38. Vincent, A. A., S. Fanning, F. C. Caira, and K. C. Williamson. 1999. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite Immunol. 21:573–581.

39. WHO. 2010. World malaria report 2010. WHO Press, Geneva, Switzerland.

40. Williamson, K. C. 2003. Pf6230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol. 25:351–359.

41. Williamson, K. C., M. D. Criscio, and D. C. Kaslow. 1993. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pf6230. Mol. Biochem. Parasitol. 58:355–358.

42. Williamson, K. C., and D. C. Kaslow. 1993. Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pf6230. Mol. Biochem. Parasitol. 62:125–127.

43. Williamson, K. C., D. B. Keister, O. Muratova, and D. C. Kaslow. 1995. Recombinant Pf6230, a Plasmodium falciparum gametocyte protein, induces antibodies that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol. Biochem. Parasitol. 75:33–42.

44. Wu, Y., et al. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pf625 and Pvs25 formulated with montanide ISA 51. PLoS One 3:e2636.